{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:35:47Z","timestamp":1715996147611},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.clinthera.2012.02.011","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T11:47:19Z","timestamp":1331639239000},"page":"926-943","source":"Crossref","is-referenced-by-count":16,"title":["Cost-Effectiveness of Tapentadol in Severe Chronic Pain in Spain: A Cost Analysis of Data From RCTs"],"prefix":"10.1016","volume":"34","author":[{"given":"Marko","family":"Obradovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ikenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Hertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Anto\u00f1anzas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiltrud","family":"Liedgens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.02.011_bib1","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(99)01311-2","article-title":"Pain: an overview","volume":"353","author":"Loeser","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.02.011_bib2","series-title":"Bonica's management of pain","article-title":"Pain terms and taxonomies of pain","author":"Turk","year":"2001"},{"key":"10.1016\/j.clinthera.2012.02.011_bib3","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/SMJ.0b013e3180f626ff","article-title":"Management of chronic non-cancer pain in the primary care setting","volume":"100","author":"Nicholson","year":"2007","journal-title":"South Med J"},{"key":"10.1016\/j.clinthera.2012.02.011_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","article-title":"Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment","volume":"10","author":"Breivik","year":"2006","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2012.02.011_bib5","series-title":"A Clinical Guide to Neuropathic Pain","author":"Galer","year":"2000"},{"key":"10.1016\/j.clinthera.2012.02.011_bib6","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1185\/030079906X132488","article-title":"painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain","volume":"22","author":"Freynhagen","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2012.02.011_bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1586\/14737175.5.6.823","article-title":"Combination pharmacotherapy for neuropathic pain: current evidence and future directions","volume":"5","author":"Gilron","year":"2005","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2012.02.011_bib8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/14737167.6.5.591","article-title":"Economic burden of chronic pain","volume":"6","author":"Phillips","year":"2006","journal-title":"Expert Rev of Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2012.02.011_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MJT.0b013e3181671c5a","article-title":"Dilemmas in chronic\/persistent pain management","volume":"15","author":"Katz","year":"2008","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2012.02.011_bib10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/AJP.0b013e318032de5d","article-title":"How effective is long-term opioid therapy for chronic noncancer pain?","volume":"23","author":"Rowbotham","year":"2007","journal-title":"Clin J Pain"},{"key":"10.1016\/j.clinthera.2012.02.011_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","article-title":"Opioids in chronic non-cancer pain: systematic review of efficacy and safety","volume":"112","author":"Kalso","year":"2004","journal-title":"Pain"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2012.02.011_bib12","first-page":"S5","article-title":"Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.clinthera.2012.02.011_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejpain.2005.01.014","article-title":"The burden of neuropathic pain: results from a cross-sectional survey","volume":"10","author":"McDermott","year":"2006","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2012.02.011_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pain.2006.06.009","article-title":"Critical issues on opioids in chronic non-cancer pain: an epidemiological study","volume":"125","author":"Eriksen","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2012.02.011_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/J354v20n03_17","article-title":"The white paper on opioids and pain: a pan-European challenge","volume":"20","year":"2006","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.clinthera.2012.02.011_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003495-200363010-00002","article-title":"Responsible prescribing of opioids for the management of chronic pain","volume":"63","author":"Nicholson","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.02.011_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/AJP.0b013e31816b58eb","article-title":"Management of expected and unexpected opioid-related side effects","volume":"24","author":"Harris","year":"2008","journal-title":"Clin J Pain"},{"key":"10.1016\/j.clinthera.2012.02.011_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1358\/dof.2006.031.12.1047744","article-title":"Tapentadol HCI","volume":"31","author":"Tzschentke","year":"2006","journal-title":"Drugs Future"},{"key":"10.1016\/j.clinthera.2012.02.011_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.107.126052","article-title":"(\u2013)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties","volume":"323","author":"Tzschentke","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2012.02.011_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"Afilalo","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2012.02.011_bib22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","article-title":"Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study","volume":"11","author":"Buynak","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2012.02.011_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12325-010-0036-3","article-title":"Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain","volume":"27","author":"Lange","year":"2010","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2012.02.011_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/03007995.2010.537589","article-title":"Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial","volume":"27","author":"Schwartz","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2012.02.011_bib25","unstructured":"Upmalis D, Okamoto A, Van Hove I, et al. Efficacy and tolerability data supporting the use of tapentadol immediate release for the relief of pain from end-stage joint disease. Annual EULAR Congress; June 11\u201314, 2008; Paris France. Abstract AB0744."},{"key":"10.1016\/j.clinthera.2012.02.011_bib26","unstructured":"Oh C, Upmalis D, Okamoto A, et al. Flexible use of tapentadol immediate release for 90 days for the treatment of low back pain and osteoarthritis pain: a safety study. Annual EULAR Congress; June 11\u201314, 2008; Paris, France. Abstract FRI0335."},{"key":"10.1016\/j.clinthera.2012.02.011_bib27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clinthera.2009.02.009","volume":"31","author":"Hartrick","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.02.011_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1358\/dot.2009.45.7.1395291","article-title":"Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule","volume":"45","author":"Tzschentke","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.clinthera.2012.02.011_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1533-2500.2010.00397.x","article-title":"Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain","volume":"10","author":"Wild","year":"2010","journal-title":"Pain Pract"},{"key":"10.1016\/j.clinthera.2012.02.011_bib30","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1097\/01.brs.0000186860.23078.a8","article-title":"Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain","volume":"30","author":"Allan","year":"2005","journal-title":"Spine"},{"key":"10.1016\/j.clinthera.2012.02.011_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3111\/13696998.2011.583303","article-title":"The prevalence, correlates and treatment of pain in Spain","volume":"14","author":"Langley","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2012.02.011_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1157\/13046566","article-title":"El dolor de espalda en la poblaci\u00f3n catalana","volume":"17","author":"Bassols","year":"2003","journal-title":"Gac Sanit"},{"key":"10.1016\/j.clinthera.2012.02.011_bib33","first-page":"129","article-title":"Efectividad, tolerabilidad y calidad de vida en el tratamiento del dolor cr\u00f3nico no oncol\u00f3gico, com tramadol de liberaci\u00f3n controlada en dosis \u00fanica diaria","volume":"11","author":"Casals","year":"2004","journal-title":"Rev Soc Esp Dolor"},{"key":"10.1016\/j.clinthera.2012.02.011_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0304-3959(95)00180-8","article-title":"Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain","volume":"64","author":"Donner","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2012.02.011_bib36","series-title":"Subdirecci\u00f3n General de Coordinaci\u00f3n Administrativa","year":"2001"},{"key":"10.1016\/j.clinthera.2012.02.011_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1524-4733.2005.03070.x","article-title":"Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability","volume":"8","author":"Barbieri","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2012.02.011_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0885-3924(00)00247-5","article-title":"Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain","volume":"21","author":"Neighbors","year":"2001","journal-title":"Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2012.02.011_bib40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10198-002-0097-6","article-title":"Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine","volume":"3","author":"Lehmann","year":"2003","journal-title":"Eur J of Health Econ"},{"key":"10.1016\/j.clinthera.2012.02.011_bib41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10198-006-0376-8","article-title":"Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany","volume":"7","author":"Greiner","year":"2006","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2012.02.011_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/J354v17n02_02","article-title":"A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain","volume":"17","author":"Frei","year":"2003","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.clinthera.2012.02.011_bib43","unstructured":"Steigerwald I, Kress GH, Kern U, et al. Effectiveness of tapentadol prolonged release for the management of severe, chronic low back pain with or without a neuropathic component. NWACWorld Anesthesia Congress; April 11\u201315, 2011; Rome, Italy. Abstract 067 plus poster."},{"key":"10.1016\/j.clinthera.2012.02.011_bib44","unstructured":"Steigerwald I, Groblschegg S, Samper D, et al. Effectiveness of tapentadol prolonged release for the management of severe, chronic low back pain by prior opioid experience. Annual Meeting of the British Pain Society; June 21\u201324, 2011; Edinburgh, Germany. Abstract plus poster."},{"key":"10.1016\/j.clinthera.2012.02.011_bib45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3111\/13696998.2011.583302","article-title":"Economic impact of potential drug-drug interactions in opioid analgesics","volume":"14","author":"Summers","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2012.02.011_bib46","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3111\/13696998.2010.529379","article-title":"The impact of pain on labor force participation, absenteeism and presenteeism in the European Union","volume":"13","author":"Langley","year":"2010","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2012.02.011_bib47","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jpain.2010.02.007","article-title":"Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians","volume":"11","author":"Gregorian","year":"2010","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2012.02.011_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jval.2011.07.002","article-title":"Stated preferences of physicians and chronic pain sufferers in the use of classic strong opioids","volume":"15","author":"Chancellor","year":"2012","journal-title":"Value Health"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T02:16:08Z","timestamp":1687313768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812000902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0149291812000902"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.02.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}